EyePoint Pharmaceuticals, Inc. (CIK: 0001314102) EDGAR, Information, Filings... CompaniesBIO.Com

EyePoint Pharmaceuticals, Inc.

Mailing address
480 PLEASANT STREET, SUITE B300, WATERTOWN, Delaware, 02472
Phone
617-926-5000
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS
Filings
N/A

EyePoint Pharmaceuticals, Inc. (CIK: 0001314102) is an American company incorporated in the state of Massachusetts. Head office is located at 480 PLEASANT STREET, SUITE B300, WATERTOWN, Massachusetts, 02472. Work in the industry 3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS. EyePoint Pharmaceuticals, Inc. is a public company and trade via Over-The-Counter (OTC).

Old names:

pSivida Corp. from 2008-19-Jun to 2018-30-Mar
pSivida LTD from 2005-20-Jan to 2008-18-Jun

Owner	Filings	Transaction Date	Type of Owner
Zaderej Karen L.	0001530968	Jul-11-2022	director
ADAMIS ANTHONY P	0001277479	Jun-23-2022	director
Pine Michael Craig	0001904458	Jan-10-2022	officer: Chief Corp Dev.&Strat. Officer
OcuMension Therapeutics	0001840315	Dec-31-2020	10 percent owner
Liu Ye	0001840407	Dec-31-2020	director
Elston George	0001429932	Nov-14-2019	officer: Chief Financial Officer
DICICCO WENDY F	0001225165	Jul-15-2019	director
Jones David Scott	0001779458	Jun-10-2019	officer: SVP & Chief Commercial Officer
GUYER DAVID R	0001277476	Jan-25-2019	director
Landis John B.	0001477283	Oct-25-2018	director
Price David	0001449336	Aug-01-2018	officer: Chief Financial Officer
ANDO GORAN	0001110748	Jun-25-2018	director
BLUM LEONARD M	0001222247	May-14-2018	officer: See Remarks
Eastman Ronald W	0001597585	Mar-28-2018	director, 10 percent owner
EW Healthcare Partners, L.P.	0001612343	Mar-28-2018	10 percent owner
Essex Woodlands Fund IX-GP, L.P.	0001652285	Mar-28-2018	10 percent owner
Essex Woodlands IX, LLC	0001652286	Mar-28-2018	10 percent owner
EW Healthcare Partners-A, L.P.	0001736240	Mar-28-2018	10 percent owner
Peterson Kristine	0001508596	Jun-27-2017	director
Paggiarino Dario A.	0001574261	Jun-27-2017	officer: Chief Medical Officer
JORN DEBORA	0001643304	Jun-27-2017	officer: EVP, Corp. & Comm'l Dev.
Lurker Nancy	0001450485	Dec-12-2016	director, officer: President and CEO
Duker Jay S.	0001630864	Dec-12-2016	director
SAVAS PETER G	0001127426	Dec-03-2015	director
ROGERS MICHAEL W	0001244159	Dec-03-2015	director
Mazzo David J	0001334549	Dec-03-2015	director
Godshall Douglas Evan	0001404227	Dec-03-2015	director
Ashton Paul	0001410243	Dec-03-2015	director, officer: President and CEO
Barry James J	0001541253	Dec-03-2015	director
Freedman Lori	0001410291	Jul-23-2015	officer: See Remarks
Ross Leonard S	0001458753	Jul-23-2015	officer: Vice President, Finance
Hopper Paul	0001355220	Oct-01-2012	director
PFIZER INC	0000078003	Aug-27-2007	10 percent owner
Soja Michael	0001410241	Jul-13-2007	officer: VP Finance, CFO & Treasurer
Finlay Aaron	0001410242	Jul-13-2007	officer: Secretary
Woodthorpe Katherine	0001410665	Jul-13-2007	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by EyePoint Pharmaceuticals, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SCHEDULE 13G/A	Document	Acc-no: 0000902664-25-004890 (34 Act) Size: KB	Nov-13-2025	005-81613 251475752
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0002013623-25-000005 ( Act) Size: 0 KB	Nov-12-2025
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001950047-25-008671 (33 Act) Size: 0 KB	Nov-12-2025	000-51122 251468592
8-K	Document	Current report filing Acc-no: 0001193125-25-270145 (34 Act) Size: KB	Nov-06-2025	000-51122 251459668
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-25-270138 (33 Act) Size: KB	Nov-06-2025	333-290867 251459650
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001193125-25-269471 (34 Act) Size: KB	Nov-06-2025	000-51122 251458226
8-K	Document	Current report filing Acc-no: 0001193125-25-265706 (34 Act) Size: KB	Nov-05-2025	000-51122 251451742
SCHEDULE 13G/A	Document	Acc-no: 0002012383-25-002572 (34 Act) Size: KB	Oct-17-2025	005-81613 251401832
8-K	Document	Current report filing Acc-no: 0001193125-25-241639 (34 Act) Size: KB	Oct-17-2025	000-51122 251398566
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-25-240658 (33 Act) Size: KB	Oct-16-2025	333-290867 251396312
FWP	Document	Filing under Securities Act Rules 163/433 of free writing prospectuses Acc-no: 0001193125-25-239375 (34 Act) Size: KB	Oct-15-2025	333-290867 251393253
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-25-239161 (33 Act) Size: KB	Oct-14-2025	333-290867 251392644
S-3ASR	Document	Automatic shelf registration statement of securities of well-known seasoned issuers Acc-no: 0001193125-25-239050 (33 Act) Size: KB	Oct-14-2025	333-290867 251392021
8-K	Document	Current report filing Acc-no: 0001193125-25-239008 (34 Act) Size: KB	Oct-14-2025	000-51122 251391813
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001429932-25-000005 ( Act) Size: 0 KB	Sep-22-2025
SCHEDULE 13G/A	Document	Acc-no: 0000902664-25-003516 (34 Act) Size: KB	Aug-12-2025	005-81613 251204592
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0001193125-25-175479 (33 Act) Size: KB	Aug-07-2025	333-289373 251194691
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001193125-25-175418 (34 Act) Size: KB	Aug-07-2025	000-51122 251193890
8-K	Document	Current report filing Acc-no: 0000950170-25-103527 (34 Act) Size: KB	Aug-06-2025	000-51122 251187409
8-K/A	Document	Amendment to Current report filing Acc-no: 0000950170-25-099413 (34 Act) Size: KB	Jul-29-2025	000-51122 251158036

Recent 20 filings. View all EyePoint Pharmaceuticals, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

EyePoint Pharmaceuticals, Inc. overview
EyePoint Pharmaceuticals, Inc. job
EyePoint Pharmaceuticals, Inc. stock
EyePoint Pharmaceuticals, Inc. ownership
EyePoint Pharmaceuticals, Inc. CEO
EyePoint Pharmaceuticals, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.